Abstract:Premature ovarian insufficiency (POI) occurs in at least 1% of all women and causes life-long health problems and psychological stress. Infertility caused by POI used to be considered absolute, with infertility treatment having little or no value. Generally, it has been thought that medicine can provide little service to these patients. The etiology of POI has been found to be genetic, chromosomal, and autoimmune. In addition, the increasing numbers of cancer survivors are candidates for iatrogenic POI, along with patients who have undergone ovarian surgery, especially laparoscopic surgery. Over 50 genes are known to be causally related to POI, and the disease course of some cases has been clarified, but in most cases, the genetic background remains unexplained, suggesting that more genes associated with the etiology of POI need to be discovered. Thus, in most cases, the genetic background of POI has not been clarified. Monosomy X is well known to manifest as Turner’s syndrome and is associated with primary amenorrhea, but recent studies have shown that some women with numerical abnormalities of the X chromosome can have spontaneous menstruation up to their twenties and thirties, and some even conceive. Hormone replacement therapy (HRT) is recommended for women with POI from many perspectives. It alleviates vasomotor and genitourinary symptoms and prevents bone loss and cardiovascular disease. POI has been reported to reduce quality of life and life expectancy, and HRT may help improve both. Most of the problems that may occur with HRT in postmenopausal women do not apply to women with POI; thus, in POI, HRT should be considered physiological replacement of estrogen (+progesterone). This review describes some new approaches to infertility treatment in POI patients that may lead to new treatments for POI, along with the development of more sensitive markers of secondary/preantral follicles and genetic diagnosis.

Advances in Biomaterials and Regenerative Medicine for Primary Ovarian Insufficiency Therapy

An Update on Primary Ovarian Insufficiency

Insights into Stem Cell Therapy for Premature Ovarian Insufficiency

Therapeutic options for premature ovarian insufficiency: an updated review

The Activation of Residual Dormant Follicles by Human Chorionic Gonadotropin (HCG) in Vivo: a Novel Treatment for Premature Ovarian Insufficiency

Stem cell-derived extracellular vesicles: A novel and potential remedy for primary ovarian insufficiency

Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency

Advances in stem cell therapy for premature ovarian failure

Stem cell-based therapeutic potential in female ovarian aging and infertility

Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics

Stem Cell-Based Therapeutic Strategies for Premature Ovarian Insufficiency and Infertility: A Focus on Aging

Premature ovarian insufficiency: pathogenesis and therapeutic potential of mesenchymal stem cell

Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency

Biological therapies for premature ovarian insufficiency: what is the evidence?

Research Progress on the Etiology and Treatment of Premature Ovarian Insufficiency

Research progress on the mechanism of exosomes derived from mesenchymal stem cell in the treatment of primary ovarian insufficiency

Application of stem cells in premature ovarian insufficiency

Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI)

Current mechanisms of primordial follicle activation and new strategies for fertility preservation.

Complementary and Alternative Medicine for Premature Ovarian Insufficiency: A Review of Utilization and Mechanisms

Identifying therapeutic targets for primary ovarian insufficiency through integrated genomic analyses